TELMISARTAN 40 MG + CILNIDIPINE 10 MG + METOPROLOL SUCCINATE (ER) 23.75 MG

Product Details

TELMISARTAN 40 MG + CILNIDIPINE 10 MG + METOPROLOL SUCCINATE (ER) 23.75 MG

The combination of Telmisartan 40mg + Cilnidipine 10mg + Metoprolol 25mg ER (extended release) is indicated for the management of hypertension (high blood pressure) in adults. It helps to lower high blood pressure thus reduces chances of future heart attack and stroke. Hypertension is the term used to describe the presence of high blood pressure. The blood pressure is generated by the force of the blood pumped from the heart against the blood vessels. Thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessel.

Telmisartan 40mg + Cilnidipine 10mg + Metoprolol 25mg ER (extended release) helps to lower blood pressure by targeting multiple pathways involved in blood pressure regulation. Chronic hypertension can lead to serious complications such as kidney disease, vision problems, and peripheral arterial disease. Controlling blood pressure with this medication reduces the risk of these complications and helps preserve organ function.

It is typically taken orally once daily with food Swallow the tablet or extended-release tablet whole with a full glass of water. Do not crush, break, or chew it.

Store the medication at room temperature, away from moisture and heat. Keep it out of reach of children

Common side effects : Dizziness or lightheadedness Fatigue or weakness Headache Edema (fluid retention) Hypotension (low blood pressure) Bradycardia (slow heart rate) Gastrointestinal disturbances such as nausea or diarrh

Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding. Avoid use of this drug during pregnancy and prescribe an alternative. Evidence has demonstrated fetal abnormalities or risks when used during pregnancy.

This medication combination should be used with caution in patients with impaired liver or kidney function. Patients should be monitored regularly for signs of hypotension, especially when initiating therapy or adjusting the dosage. Abrupt discontinuation of beta-blockers like metoprolol may exacerbate angina or precipitate myocardial infarction, so dosage should be gradually tapered if discontinuation is necessary. Metoprolol may cause changes in blood sugar levels. Also, this medicine may cover up the symptoms of low blood sugar (including fast heartbeat) and increase the risk for serious or prolonged hypoglycemia (low blood sugar). Check with your doctor if you notice a change in your normal symptoms. Dizziness, lightheadedness, or even fainting may occur when you get up suddenly from a lying or sitting position. Getting up slowly may help lessen this problem. Also, lying down for a while may relieve the dizziness or lightheadedness.

"Product Information: MICARDIS(R) oral tablets, telmisartan oral tablets. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, 2009 Product Information: Telmisartan. Boehringer Ingelheim, US, 98. Product Information: Lopressor(R) oral tablets, metoprolol tartrate oral tablets. Validus Pharmaceuticals, LLC (per FDA), Parsippany, NJ, 2013. "https://www.centaurpharma.com/downloads/CENTAPRES.pdf https://hypertension.ca/

Telmisartan: Telmisartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to its receptors, leading to vasodilation and lowering of blood pressure. Cilnidipine: Cilnidipine is a calcium channel blocker (CCB) with dual blocking activity on L-type and N-type calcium channels, resulting in vasodilation and reduction of blood pressure. Metoprolol Succinate: Metoprolol is a beta-blocker that competitively blocks beta-adrenergic receptors, thereby reducing heart rate, cardiac output, and blood pressure.

Cardiovascular Agent